Terms: = Lung cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4
190 results:
1. Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization.
Sun X; Nong M; Meng F; Sun X; Jiang L; Li Z; Zhang P
J Transl Med; 2024 Apr; 22(1):353. PubMed ID: 38622716
[TBL] [Abstract] [Full Text] [Related]
2. An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms.
Pelosi G; Melocchi V; Dama E; Hofman P; De Luca M; Albini A; Gemelli M; Ricotta R; Papotti M; La Rosa S; Uccella S; Harari S; Sonzogni A; Asiedu MK; Wigle DA; Bianchi F
Exp Mol Pathol; 2024 Feb; 135():104882. PubMed ID: 38237798
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma.
Mishra S; Srivastava P; Pandey A; Shukla S; Agarwal A; Husain N
Lab Invest; 2024 Feb; 104(2):100301. PubMed ID: 38092180
[TBL] [Abstract] [Full Text] [Related]
4. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
Booth L; Poklepovic A; Hancock JF; Dent P
Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
[TBL] [Abstract] [Full Text] [Related]
5. her4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract] [Full Text] [Related]
6. Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell lung cancer.
Ilnytskyy Y; Petersen L; McIntyre JB; Konno M; D'Silva A; Dean M; Elegbede A; Golubov A; Kovalchuk O; Kovalchuk I; Bebb G
Cancer Genomics Proteomics; 2023; 20(5):417-432. PubMed ID: 37643782
[TBL] [Abstract] [Full Text] [Related]
7. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
Jiang Y; Fang X; Xiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2023 May; 30(6):5337-5349. PubMed ID: 37366888
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract] [Full Text] [Related]
9. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract] [Full Text] [Related]
10. Tastin promotes non-small-cell lung cancer progression through the erbb4, PI3K/AKT, and ERK1/2 pathways.
Yue A; Chen M; Dai S; Zhang Y; Wei W; Fan L; Wang F; Zhang F; Yu H; Lu Y; Lei Y
Exp Biol Med (Maywood); 2023 Mar; 248(6):519-531. PubMed ID: 36691332
[TBL] [Abstract] [Full Text] [Related]
11. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
Boch T; Köhler J; Janning M; Loges S
Cancer Biol Med; 2022 Dec; 19(11):1543-64. PubMed ID: 36476337
[TBL] [Abstract] [Full Text] [Related]
12. Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell lung cancer (NSCLC)-A Single Center, Retrospective Observational Study.
Stephan-Falkenau S; Streubel A; Mairinger T; Kollmeier J; Misch D; Thiel S; Bauer T; Pfannschmidt J; Hollmann M; Wessolly M; Blum TG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293366
[TBL] [Abstract] [Full Text] [Related]
13. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract] [Full Text] [Related]
14. A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif
Liu G; Xue J; Wang Y; Liu Z; Li X; Qu D; Su Z; Xu K; Qu X; Qu Z; Sun L; Cao M; Wang Y; Chen X; Yu J; Liu L; Deng Q; Zhao Y; Zhang L; Yang H
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2585-2593. PubMed ID: 35771264
[TBL] [Abstract] [Full Text] [Related]
15. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
16. Identification of genes and pathways associated with sex in Non-smoking lung cancer population.
Xu L; Wang L; Cheng M
Gene; 2022 Jul; 831():146566. PubMed ID: 35577039
[TBL] [Abstract] [Full Text] [Related]
17. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
18. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
19. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant lung Adenocarcinoma.
Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
[TBL] [Abstract] [Full Text] [Related]
20. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.
Ma Y; Qi B; Ning M; Zhang L; An Z; Zhao J
Eur Biophys J; 2022 Apr; 51(3):283-295. PubMed ID: 35307752
[TBL] [Abstract] [Full Text] [Related]
[Next]
